Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AI Image
Lead poisoning is a widespread but preventable health threat that contributes to more than 3.5 million deaths globally each year and puts hundreds of millions of children at risk, the World Health Organization (WHO) said.
Marking International Lead Poisoning Prevention Week 2026, WHO urged countries to accelerate prevention efforts amid growing global momentum to tackle lead exposure.
Also read: Lead Found In Everyday Vegetables - Reveals A Bengaluru Study
Children are particularly vulnerable to lead because their developing brains and nervous systems are highly susceptible to its toxic effects. Even low levels of exposure can cause irreversible harm, affecting learning, behavior and development.
“Lead poisoning should not be stealing children's potential in 2026,” said Bruce Gordon, Director a.i. of WHO’s Department of Environment, Climate Change, One Health and Migration.
“We know where many exposures come from and we know how to prevent them. Countries now need to move upstream, removing lead from products and environments before it reaches a child's bloodstream. WHO is working with governments and partners to help turn that evidence into action,” Gordon added.
There is no known safe level of lead exposure, WHO warned. Exposure can occur through paint, cookware, cosmetics, spices, informal recycling and industrial contamination, among other sources.
Lead affects multiple organs and can contribute to cardiovascular and kidney disease in adults. In children, exposure can cause lasting damage to brain function and development. Its effects may go undetected until significant harm has occurred.
Lead is distributed to the brain, liver, kidney and bones. It is stored in the teeth and bones, where it can accumulate over time. Human exposure is assessed through the measurement of lead in blood.
Fewer than half of countries had confirmed legally binding controls on lead paint, according to WHO's latest published global assessment.
This year's International Lead Poisoning Prevention Week theme, “From Detection to Prevention,” highlights the need for stronger policies, better enforcement of safety standards and greater public awareness to eliminate lead hazards at their source.
WHO Member States have recognized lead exposure as a pressing public health concern and mandated the development of a Global Action Plan on Lead Mitigation, which will be presented to the World Health Assembly in 2027.
The WHO will also launch the PREVENT Technical Package on Lead Poisoning Prevention in 2027. It will provide practical guidance to help countries identify major exposure sources, prioritize interventions, strengthen regulations and track progress.
Last year, WHO joined partners in the Lead Poisoning Prevention Initiative to strengthen laboratory capacity for blood lead testing, supporting the monitoring and early detection of exposure.
The initiative will provide technical support and build laboratory capacity in Brazil, five states in India, Nepal and six sub-Saharan African countries: Ethiopia, Ghana, Malawi, Rwanda, South Africa and the United Republic of Tanzania.
Preventing lead exposure can also reduce health care costs, improve educational outcomes and support healthier, more productive societies.
The WHO urged countries to move beyond detecting lead exposure and adopt comprehensive prevention strategies such as:
Credit: BBC/PA News Agency
Scottish swimmer Archie Goodburn has welcomed the UK government’s plans to review progress in brain cancer research after years of campaigning for better treatment and greater investment in research.
Goodburn, 25, revealed in 2024 that he had been diagnosed with three inoperable brain tumors. In August, he broke down during an interview on BBC Breakfast as he spoke about the challenges faced by patients with brain cancer and their families.
He appealed to the government to invest more in research, urging it to “give us a chance to fight for our lives.” His plea led to a meeting with Prime Minister Andy Burnham.
The government has now announced a new national brain cancer clinical lead and a review of progress in brain cancer research, with the aim of helping patients access treatments sooner, the BBC reported.
Goodburn thanked the prime minister, saying all three of his requests had been “promised to some extent,” although the details still needed to be worked out.
Burnham described Goodburn as an “inspiration to us all” and said he was “delighted” to welcome him to Downing Street.
“He has spoken passionately about the need for change on brain cancer, and he's right: progress hasn't been good enough, here or anywhere else. Families facing this disease can't afford to wait,” Burnham said.
According to the BBC, the review will be led by Professor Anthony Chalmers, chair of clinical oncology at the University of Glasgow. It will assess progress in brain cancer research since 2018 and identify “what is still holding progress back.”
The review will be followed by a national cancer plan aimed at getting new treatments “out of the lab and to patients faster,” Downing Street said.
The prime minister has also asked the Medicines and Healthcare products Regulatory Agency (MHRA) to complete its review of regulations for medicines used to treat rare conditions sooner.
Goodburn has urged the regulator to finish the review within two years rather than three, bringing forward potential changes that could help patients access new treatments sooner.
Read More: Saba Ali Khan Opens Up About Brain Tumour: Can It Go Unnoticed If You Walk, Talk And Work Normally?
Scottish First Minister John Swinney, who also recently met Goodburn, highlighted the Scottish government's commitment to supporting more clinical trials.
“We are proud to support national leadership for brain cancer through the Scottish Adult Neuro-Oncology Network,” Swinney said.
The network brings together clinicians, patients and voluntary sector representatives to improve care for people with brain cancer across Scotland.
“We will give careful consideration to any further role which Scotland could play to give people living with brain cancer a faster route from research to treatment,” he added.
READ: Survival In Aggressive Brain Tumors Improves By Up To 50% in India, Say Doctors
The Edinburgh-born swimmer sought medical tests after experiencing numbness and seizures while training for the 2024 Olympic trials. He was diagnosed with three large oligodendrogliomas, a rare type of tumor that can affect the brain and spinal cord.
He underwent chemotherapy and radiotherapy, but surgery to remove the tumors was not possible.
Despite his diagnosis, Goodburn competed at the 2026 Commonwealth Games in Glasgow, reaching the final of the 50-meter breaststroke but narrowly missing out on a medal.
Charity Brain Tumour Research has described brain tumors as the cancer most likely to kill people under 40 in the UK.
“One of my dreams is that we see a future where brain cancer isn't the biggest killer of patients under 40,” Goodburn said during the Commonwealth Games.
Credit: AI
Retatrutide, an experimental loss drug being called the 'Godzilla' of weight loss jabs, has been reported to cause 129 symptoms, including burning sensation on skin, panic attack, a racing heartbeat and depression. It earned the nickname after clinical trials indicated that it could be more powerful than Ozempic and Mounjaro.
The discovery has raised concerns, especially amid the growing use of the drug outside clinical trials. Retatrutide is still being studied and has not yet been approved for general use but it is being bought illegally in the UK as well as across the world.
According to Daily Mail, researchers from the University of Pennsylvania, analysed 148,640 Reddit posts related to retatrutide and identified 13,589 users who claimed to be taking retatrutide and analysed the side effects they reported. Of these, 7,823 reported at least one side effect, researchers identified 129 different symptoms.
The reports included physical symptoms as well as psychological complaints. But it does not prove that this weight loss drug is directly responsible for these side effects. The study was published in JAMA Network Open.
Social media reports can help identify safety concerns, but they have limitations. Researchers cannot independently verify every user’s medical history, the product they took, its ingredients or whether another condition could explain their symptoms.
The side effects were split into 14 different categories, including gastrointestinal problems, mental disorders, heart problems and skin changes. The most common side effect was increased appetite surprisingly which was seen in almost one in five users, affecting 1,336 people.
Fatigue was the second most reported symptom, which was flagged by around 15% of the users, which means almost 1, 188 patients. Nausea, on the other hand, was on top of the list of gastrointestinal issues, affecting fewer than one in 10.
Retatrutide is being developed by pharmaceutical company Eli Lilly as a treatment for obesity. It works on three hormone receptors involved in regulating appetite, blood sugar and energy balance: GIP, GLP-1 and glucagon.
The drug has attracted attention because clinical trials have shown substantial weight loss. In a Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose lost an average of 24.2% of their body weight over 48 weeks.
It also delivered nearly 21% average weight loss in people with type 2 diabetes and obesity, according to results from a large Phase 3 trial published in The Lancet.
In the TRIUMPH-2 trial, people who received the highest 12 mg dose lost an average of 20.8% of their body weight over 80 weeks, equivalent to about 49.6 pounds or 22.5 kg.
However, promising results do not mean the drug is suitable for unsupervised use, especially since it is unapproved.
Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs
In controlled clinical trials, the most frequently reported side effects have included nausea, diarrhoea, vomiting and constipation. These gastrointestinal problems were generally more common at higher doses and during dose increases.
Researchers have also reported increased heart rate and skin sensitivity in some participants. In the Phase 2 trial, adverse events related to skin sensitivity were reported in 7% of participants receiving retatrutide, compared with 1% in the placebo group.
The symptoms reported in online discussions, including panic attacks and depression, require careful interpretation. Their appearance in user posts does not, by itself, prove that the drug caused them or establish how frequently they occur among people taking retatrutide under medical supervision.
Retatrutide remains under study, which means its safety profile is still being assessed by researchers. Products sold online or through unlawful ways may not contain the right advertised drug.
Professor Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, warned against purchasing unlicensed weight-loss products online. “I would urge people to avoid buying unlicensed weight-loss products online,” he said, according to Daily Mail. “There is no certainty about what these products contain, and without proper regulatory oversight there is a risk of adverse effects.”
© $2026 Times Horizon Private Limited